ChemoCentryx Newswire

ChemoCentryx Newswire

Comprehensive Real-Time News Feed for ChemoCentryx.

Results 1 - 20 of 163 in ChemoCentryx

  1. What Investors are Making of These Biotech Stocks? a " ChemoCentryx, Alder Biopharma, Neothetics,...Read the original story

    Yesterday | Freshnews

    Economic uncertainty and pricing pressures remain the Biotech industry's biggest threats, but despite the challenges, several companies continue to impress. Ahead of today's session, Stock-Callers.com has issued alerts on the following equities: ChemoCentryx Inc. , Alder Biopharmaceuticals Inc. , Neothetics Inc. , and OvaScience Inc. .

    Comment?

  2. Zacks: ChemoCentryx Inc (NASDAQ:CCXI) Given $13.00 Consensus Price Target by BrokeragesRead the original story w/Photo

    Friday Jun 17 | Daily Political

    ChemoCentryx Inc has been assigned an average broker rating score of 3.00 from the one analysts that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.

    Comment?

  3. Zacks: ChemoCentryx Inc (NASDAQ:CCXI) Given $13.00 Consensus Price Target by BrokeragesRead the original story w/Photo

    Friday Jun 17 | AmericanBankingNews.com

    ChemoCentryx Inc has received an average broker rating score of 3.00 from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation.

    Comment?

  4. Positive Top-Line Results Reported for Orphan Drug CCX168 in Treatment of ANCA-Associated VasculitisRead the original story

    Thursday Jun 16 | P&T Community

    ChemoCentryx, Inc., has announced positive top-line results from its phase 2 CLASSIC study of CCX168 in patients with antineutrophil cytoplasmic auto-antibody -associated vasculitis . The study's safety objective was achieved: The drug was found to be well tolerated in patients with AAV when added to the current standard-of-care regimen of chronic high-dose steroids.

    Comment?

  5. ChemoCentryx's lead product candidate shows positive results in mid-stage AAV studyRead the original story w/Photo

    Thursday Jun 16 | Seeking Alpha

    A Phase 2 study, CLASSIC, evaluating the safety of ChemoCentryx's Orphan Drug-tagged CCX168 in patients with anti-neutrophil cytoplasmic auto-antibody-associated vasculitis met its objectives . The double-blind, placebo-controlled trial assessed the safety of CCX168 in 42 patients with newly diagnosed or relapsed AAV who all received standard-of-care treatment or the chemo agent cyclophosphamide).

    Comment?

  6. ChemoCentryx Announces Positive Top-Line Results for CCX168 from the...Read the original story w/Photo

    Thursday Jun 16 | GlobeNewswire

    ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development -- Safety study objective achieved: CCX168 shown to be well tolerated in patients with ANCA-associated vasculitis when added to current standard of care regimen -- MOUNTAIN VIEW, Calif., June 16, 2016 -- ChemoCentryx, Inc., today announced positive top-line results from its Phase II CLASSIC PRIority MEdicines initiative, which supports accelerated assessment of investigational therapies addressing unmet medical need.

    Comment?

  7. Global Immunotherapy Drugs 2016-2020 Prevention, Management, Mechanisms, Cause and Symptoms ReportRead the original story

    Wednesday Jun 15 | Emailwire.com

    ... Pharmaceutical Biothera Boehringer Ingelheim Can-Fite BioPharma Celgene Celldex Therapeutics Celltrion Cel-Sci ChemoCentryx Chugai Pharmaceutical Coherus BioSciences CTI BioPharma CureVac Cytos Biotechnology Daiichi Sankyo Eisai Eli Lilly Fortress ...

    Comment?

  8. ChemoCentryx Inc (CCXI) Stake Increased by BlackRock Fund AdvisorsRead the original story w/Photo

    Friday Jun 3 | Daily Political

    BlackRock Fund Advisors raised its stake in ChemoCentryx Inc by 2.0% during the first quarter, Holdings Channel reports. The firm owned 1,279,222 shares of the biopharmaceutical company's stock after buying an additional 25,382 shares during the period.

    Comment?

  9. Global Autoimmune Drugs Market 2016-2020 Types, Indications and Principle ReportRead the original story

    Thursday Jun 2 | Emailwire.com

    ... Antares Pharma Astellas Pharma AstraZeneca Baxter Boehringer Ingelheim Can-Fite BioPharma Celgene Celltrion ChemoCentryx Coherus BioSciences Daiichi Sankyo Eisai Eli Lilly Gilead Sciences GSK Hospira Idera Pharmaceuticals Immunomedics ImmuPharma ...

    Comment?

  10. ChemoCentryx Inc (CCXI) Director James L. Tyree Sells 5,544 Shares of StockRead the original story w/Photo

    May 25, 2016 | Daily Political

    ChemoCentryx Inc Director James L. Tyree sold 5,544 shares of ChemoCentryx stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $4.39, for a total transaction of $24,338.16.

    Comment?

  11. ChemoCentryx Inc (CCXI) Director James L. Tyree Sells 5,544 SharesRead the original story w/Photo

    May 24, 2016 | AmericanBankingNews.com

    ChemoCentryx Inc Director James L. Tyree sold 5,544 shares of the company's stock in a transaction dated Monday, May 23rd. The shares were sold at an average price of $4.39, for a total transaction of $24,338.16.

    Comment?

  12. ChemoCentryx Announces Presentation of Positive Results from Phase II ...Read the original story w/Photo

    May 23, 2016 | GlobeNewswire

    ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress -- Treatment with CCX168 successful in achieving clinical efficacy endpoints while eliminating high-dose oral corticosteroids from current standard-of-care regimen, suggesting a new treatment paradigm for ANCA-Associated Vasculitis -- -- Separately, utilization of CRISPR-Cas9 to create novel models of complement mediated renal diseases such as aHUS and C3 glomerulopathy highlighted i n poster presentation -- MOUNTAIN VIEW, Calif., May 23, 2016 -- ChemoCentryx, Inc., , a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced the presentation of positive results from its Phase II ... (more)

    Comment?

  13. ChemoCentryx Inc (CCXI) Stock Rating Reaffirmed by Cowen and CompanyRead the original story w/Photo

    May 23, 2016 | Daily Political

    's stock had its "hold" rating reissued by equities research analysts at Cowen and Company in a research report issued to clients and investors on Thursday. Separately, Zacks Investment Research upgraded ChemoCentryx from a "hold" rating to a "buy" rating and set a $2.75 price objective for the company in a report on Wednesday, April 27th.

    Comment?

  14. ChemoCentryx Inc (NASDAQ:CCXI) Receives Consensus Recommendation of...Read the original story w/Photo

    May 21, 2016 | Daily Political

    Shares of ChemoCentryx Inc have been assigned an average broker rating score of 3.00 from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation.

    Comment?

  15. Investment Analysts' Updated EPS Estimates for May, 19th (CCXI,...Read the original story w/Photo

    May 19, 2016 | AmericanBankingNews.com

    The analysts wrote, "Chemocentryx's Investor Meeting offered a review of lead candidates CCX168 for." " was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating.

    Comment?

  16. Cowen and Company Reiterates Hold Rating for ChemoCentryx IncRead the original story w/Photo

    May 19, 2016 | AmericanBankingNews.com

    ... in the company, valued at approximately $170,006.85. The disclosure for this purchase can be found here . ChemoCentryx ( NASDAQ:CCXI ) traded down 8.39% during trading on Thursday, reaching $4.37. 4,218,215 shares of the company's stock were ...

    Comment?

  17. ChemoCentryx Inc (CCXI) Receives Hold Rating from Cowen and CompanyRead the original story w/Photo

    May 19, 2016 | AmericanBankingNews.com

    ... funds recently bought and sold shares of CCXI. California State Teachers Retirement System raised its stake in ChemoCentryx by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 51,873 shares of the biopharmaceutical ...

    Comment?

  18. ChemoCentryx Inc (CCXI) Director Thomas A. Edwards Purchases 50,000 SharesRead the original story w/Photo

    May 19, 2016 | Daily Political

    ChemoCentryx Inc Director Thomas A. Edwards acquired 50,000 shares of the company's stock in a transaction on Tuesday, May 17th. The stock was acquired at an average price of $4.05 per share, for a total transaction of $202,500.00.

    Comment?

  19. New Market Research Report: Psoriasis - Pipeline Review, H1 2016Read the original story w/Photo

    May 19, 2016 | SBWire

    ... Discovery Holdings PLC, Can-Fite BioPharma Ltd., Celgene Corporation, Cellceutix Corporation, Celltrion, Inc., ChemoCentryx, Inc., Chipscreen Biosciences Ltd, ChironWells GmbH, Coherus BioSciences, Inc., Compugen Ltd., Convoy Therapeutics, Inc., ...

    Comment?

  20. Insider Buying: ChemoCentryx Inc (CCXI) Director Purchases 50,000 Shares of StockRead the original story w/Photo

    May 18, 2016 | AmericanBankingNews.com

    ChemoCentryx Inc Director Thomas A. Edwards acquired 50,000 shares of the firm's stock in a transaction dated Tuesday, May 17th. The shares were purchased at an average price of $4.05 per share, with a total value of $202,500.00.

    Comment?